Looking Ahead: 10 Analyst Predictions for DexCom
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 26 2025
0mins
Should l Buy DXCM?
Source: Benzinga
Analyst Ratings Overview: Recent evaluations of DexCom (NASDAQ: DXCM) show a mix of bullish and somewhat bullish sentiments, with 4 analysts rating it as 'Buy' and 2 as 'Indifferent' over the last 30 days, while the average price target has increased to $99.3.
Financial Performance Insights: DexCom has demonstrated strong financial metrics, including a revenue growth rate of 15.21%, a net margin of 15.54%, and a return on equity of 7.43%, although it faces challenges with a high debt-to-equity ratio of 1.0.
Market Positioning: The company's market capitalization is below industry averages, which may reflect its growth potential and operational scale compared to peers in the healthcare sector.
Analyst Predictions and Insights: Analysts provide qualitative ratings and price targets based on market conditions and company performance, offering valuable insights for investors regarding DexCom's future stock performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DXCM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DXCM
Wall Street analysts forecast DXCM stock price to rise
16 Analyst Rating
13 Buy
2 Hold
1 Sell
Strong Buy
Current: 68.740
Low
68.00
Averages
82.54
High
100.00
Current: 68.740
Low
68.00
Averages
82.54
High
100.00
About DXCM
DexCom, Inc. is a medical device company. The Company is primarily focused on the design, development, and commercialization of continuous glucose monitoring (CGM), systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6, Dexcom G7, Stelo, Dexcom Share, and Dexcom ONE. The Company enables people to take control of health through innovative biosensing technology. Dexcom G6 is its integrated continuous glucose monitoring system (iCGM). Stelo is designed specifically for people with type II diabetes who do not use insulin as the first over-the-counter glucose biosensor in the United States. The Dexcom Share remote monitoring system, offered for use with any Dexcom system, uses an app on the patient’s compatible mobile device. Its Dexcom G7 is for adults and children (2+ years) living with type I or type II diabetes who are on any insulin or medications, at risk of hypoglycemia, and those with gestational diabetes.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Intuitive Surgical and DexCom: Future Prospects Analysis
- Challenges for Intuitive Surgical: Intuitive Surgical has faced tariffs and competition from Medtronic's new Hugo system, resulting in a 13% stock price decline over the past year; however, it is expected to benefit from the growing surgical demand due to an aging population over the next decade, maintaining its market leadership.
- Market Potential: By 2034, the U.S. population aged 65 and older is projected to exceed those aged 18 and under, which will drive demand for Intuitive Surgical's da Vinci system, allowing for revenue and earnings growth despite competitive pressures due to its high switching costs and innovative capabilities.
- DexCom's Market Opportunities: DexCom's leadership in the CGM market remains intact despite last year's minor product recalls, with potential to expand its market share by targeting over 9 million insured diabetes patients who are not currently using CGM technology.
- New Product Development: DexCom's new product Stelo has attracted over 500,000 users in the U.S., targeting the large market of over 40% of the population with prediabetes, indicating significant growth potential in the non-diabetic patient segment, which is expected to drive future company growth.
See More
Intuitive Surgical and DexCom's Growth Prospects Amid Challenges
- Growing Market Demand: Intuitive Surgical faces tariffs and competitive pressures in 2025, yet its leadership in the robotic-assisted surgery market and the aging population trend are expected to drive demand growth over the next decade, with projections indicating that by 2034, the U.S. population aged 65 and older will surpass those under 18, enhancing its market potential.
- Competitive Pressure Management: Despite Medtronic's Hugo system gaining competitive clearance in the U.S., Intuitive Surgical can leverage its high switching costs and innovative capabilities to mitigate tariff impacts, with its installed base of 11,106 da Vinci devices poised to generate significant revenue growth.
- DexCom's Market Opportunities: DexCom's continuous glucose monitoring devices have substantial market potential among diabetes patients, as last year's product recalls affected only a small number of users, with over 9 million patients in the U.S. having insurance coverage but not utilizing the technology, indicating strong growth prospects.
- Attractive New Products: The launch of DexCom's Stelo product, which received clearance in 2024 and attracted over 500,000 users, targets the over 40% of the U.S. population with prediabetes, further expanding its market share and expected to drive future growth for the company.
See More
Investigation into DexCom Officers' Fiduciary Duties
- Shareholder Rights Investigation: Halper Sadeh LLC is investigating whether certain officers and directors of DexCom, Inc. breached their fiduciary duties to shareholders, which could impact corporate governance and shareholder rights.
- Legal Relief Options: Long-term shareholders of DexCom may seek corporate governance reforms, return of funds, or court-approved financial awards, thereby enhancing their legal standing and rights protection.
- Importance of Participation: Shareholder involvement can improve company policies, practices, and oversight mechanisms, promoting transparency and accountability, which can enhance management efficiency and shareholder value.
- Global Investor Representation: Halper Sadeh LLC represents investors worldwide, focusing on combating securities fraud and corporate misconduct, having successfully implemented corporate reforms and recovered millions for defrauded investors.
See More
DexCom Positioned to Benefit from GLP-1 Drug Boom
- Market Opportunity: DexCom estimates over 9 million patients in the U.S. have reimbursement for CGM devices but have yet to adopt them, indicating a massive growth potential that could be further driven by the rise of GLP-1 drugs, thereby boosting the company's revenue.
- Complementary Relationship: Studies show that using CGM devices alongside GLP-1 medications significantly improves health outcomes for diabetes patients, allowing DexCom to benefit from the popularity of GLP-1 drugs without needing to develop new therapies, creating a win-win situation.
- Innovation-Driven Growth: DexCom's continuous innovations and market expansions have historically led to solid financial results, and the company is expected to continue benefiting from the growth trends associated with GLP-1 drugs as it secures reimbursement for more patients in various countries.
- Investment Appeal: Given DexCom's market potential and ongoing innovations, investing $10,000 in its shares today is considered a wise move, especially as the company stands to profit from the GLP-1 drug boom.
See More
DexCom Benefits from the Rise of GLP-1 Medications
- Market Opportunity: DexCom estimates that over 9 million patients in the U.S. are eligible for CGM device reimbursement but have yet to opt in, indicating a substantial market potential that, combined with the rise of GLP-1 drugs, is expected to drive demand for its devices.
- Product Complementarity: Studies show that using CGM devices alongside GLP-1 medications significantly improves health management for diabetes patients, with physicians increasingly prescribing both, further solidifying DexCom's leadership position in the market.
- Innovation and Expansion: DexCom's continuous technological innovations and market expansions have historically driven solid financial results, and with the rise of GLP-1 drugs, the company's growth outlook appears very promising.
- Investment Appeal: With the boost from GLP-1 medications, DexCom's stock is viewed as attractive, and investing $10,000 now could yield substantial returns in the future, even though the company was not included in the Motley Fool Stock Advisor's list of top stocks.
See More
DexCom to Present Company Update at 47th Annual Raymond James Conference
- Conference Schedule: DexCom will present a company update at the 47th Annual Raymond James Institutional Investors Conference on March 2, 2026, with the presentation set to begin at approximately 1:05 PM EST, aimed at engaging investor interest in the company's developments.
- Webcast Details: The live presentation will be webcast, with links available on the DexCom Investor Relations website, and the content will be archived for future reference, ensuring transparency and accessibility of information for stakeholders.
- Company Background: Founded in 1999, DexCom focuses on innovative biosensing technology and has pioneered glucose monitoring standards, significantly aiding diabetes management and improving quality of life for patients.
- Technological Impact: Over the past 25 years, DexCom's technology has transformed diabetes management, empowering patients to take control of their health with confidence, highlighting the company's significant role and influence in the medical technology sector.
See More
Intuitive Surgical and DexCom: Future Prospects Analysis
- Challenges for Intuitive Surgical: Intuitive Surgical has faced tariffs and competition from Medtronic's new Hugo system, resulting in a 13% stock price decline over the past year; however, it is expected to benefit from the growing surgical demand due to an aging population over the next decade, maintaining its market leadership.
- Market Potential: By 2034, the U.S. population aged 65 and older is projected to exceed those aged 18 and under, which will drive demand for Intuitive Surgical's da Vinci system, allowing for revenue and earnings growth despite competitive pressures due to its high switching costs and innovative capabilities.
- DexCom's Market Opportunities: DexCom's leadership in the CGM market remains intact despite last year's minor product recalls, with potential to expand its market share by targeting over 9 million insured diabetes patients who are not currently using CGM technology.
- New Product Development: DexCom's new product Stelo has attracted over 500,000 users in the U.S., targeting the large market of over 40% of the population with prediabetes, indicating significant growth potential in the non-diabetic patient segment, which is expected to drive future company growth.
See More
Intuitive Surgical and DexCom's Growth Prospects Amid Challenges
- Growing Market Demand: Intuitive Surgical faces tariffs and competitive pressures in 2025, yet its leadership in the robotic-assisted surgery market and the aging population trend are expected to drive demand growth over the next decade, with projections indicating that by 2034, the U.S. population aged 65 and older will surpass those under 18, enhancing its market potential.
- Competitive Pressure Management: Despite Medtronic's Hugo system gaining competitive clearance in the U.S., Intuitive Surgical can leverage its high switching costs and innovative capabilities to mitigate tariff impacts, with its installed base of 11,106 da Vinci devices poised to generate significant revenue growth.
- DexCom's Market Opportunities: DexCom's continuous glucose monitoring devices have substantial market potential among diabetes patients, as last year's product recalls affected only a small number of users, with over 9 million patients in the U.S. having insurance coverage but not utilizing the technology, indicating strong growth prospects.
- Attractive New Products: The launch of DexCom's Stelo product, which received clearance in 2024 and attracted over 500,000 users, targets the over 40% of the U.S. population with prediabetes, further expanding its market share and expected to drive future growth for the company.
See More
Investigation into DexCom Officers' Fiduciary Duties
- Shareholder Rights Investigation: Halper Sadeh LLC is investigating whether certain officers and directors of DexCom, Inc. breached their fiduciary duties to shareholders, which could impact corporate governance and shareholder rights.
- Legal Relief Options: Long-term shareholders of DexCom may seek corporate governance reforms, return of funds, or court-approved financial awards, thereby enhancing their legal standing and rights protection.
- Importance of Participation: Shareholder involvement can improve company policies, practices, and oversight mechanisms, promoting transparency and accountability, which can enhance management efficiency and shareholder value.
- Global Investor Representation: Halper Sadeh LLC represents investors worldwide, focusing on combating securities fraud and corporate misconduct, having successfully implemented corporate reforms and recovered millions for defrauded investors.
See More
DexCom Positioned to Benefit from GLP-1 Drug Boom
- Market Opportunity: DexCom estimates over 9 million patients in the U.S. have reimbursement for CGM devices but have yet to adopt them, indicating a massive growth potential that could be further driven by the rise of GLP-1 drugs, thereby boosting the company's revenue.
- Complementary Relationship: Studies show that using CGM devices alongside GLP-1 medications significantly improves health outcomes for diabetes patients, allowing DexCom to benefit from the popularity of GLP-1 drugs without needing to develop new therapies, creating a win-win situation.
- Innovation-Driven Growth: DexCom's continuous innovations and market expansions have historically led to solid financial results, and the company is expected to continue benefiting from the growth trends associated with GLP-1 drugs as it secures reimbursement for more patients in various countries.
- Investment Appeal: Given DexCom's market potential and ongoing innovations, investing $10,000 in its shares today is considered a wise move, especially as the company stands to profit from the GLP-1 drug boom.
See More
DexCom Benefits from the Rise of GLP-1 Medications
- Market Opportunity: DexCom estimates that over 9 million patients in the U.S. are eligible for CGM device reimbursement but have yet to opt in, indicating a substantial market potential that, combined with the rise of GLP-1 drugs, is expected to drive demand for its devices.
- Product Complementarity: Studies show that using CGM devices alongside GLP-1 medications significantly improves health management for diabetes patients, with physicians increasingly prescribing both, further solidifying DexCom's leadership position in the market.
- Innovation and Expansion: DexCom's continuous technological innovations and market expansions have historically driven solid financial results, and with the rise of GLP-1 drugs, the company's growth outlook appears very promising.
- Investment Appeal: With the boost from GLP-1 medications, DexCom's stock is viewed as attractive, and investing $10,000 now could yield substantial returns in the future, even though the company was not included in the Motley Fool Stock Advisor's list of top stocks.
See More
DexCom to Present Company Update at 47th Annual Raymond James Conference
- Conference Schedule: DexCom will present a company update at the 47th Annual Raymond James Institutional Investors Conference on March 2, 2026, with the presentation set to begin at approximately 1:05 PM EST, aimed at engaging investor interest in the company's developments.
- Webcast Details: The live presentation will be webcast, with links available on the DexCom Investor Relations website, and the content will be archived for future reference, ensuring transparency and accessibility of information for stakeholders.
- Company Background: Founded in 1999, DexCom focuses on innovative biosensing technology and has pioneered glucose monitoring standards, significantly aiding diabetes management and improving quality of life for patients.
- Technological Impact: Over the past 25 years, DexCom's technology has transformed diabetes management, empowering patients to take control of their health with confidence, highlighting the company's significant role and influence in the medical technology sector.
See More
